Modern therapy of radioactive iodine-refractory differentiated thyroid cancer: resolution of the Expert Council

  • Authors: Rumyantsev PO1, Gorbunova VA2, Podvyaznikov SO3, Zhukov NV4, Isaev PA5, Krylov VV5, Mudunov AM2, Rodichev AA5, Shavarova EK6,7
  • Affiliations:
    1. Endocrinology Research Center of the Ministry of Health of the Russian Federation
    2. N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
    3. Russian Medical Academy of Postgraduate Education, of the Ministry of Health of the Russian Federation
    4. Dmitriy Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology of the Ministry of Health of the Russian Federation
    5. A.F.Tsyba Medical Radiological Scientific Center, branch of National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
    6. People’s Friendship University
    7. City Clinical Hospital №64
  • Issue: Vol 18, No 3 (2016)
  • Pages: 48-51
  • Section: Articles
  • URL: https://journals.rcsi.science/1815-1434/article/view/27085
  • ID: 27085

Cite item

Full Text

Abstract

The meeting of experts, concerning the treatment of thyroid cancer was held in Moscow in June 2016. The aim of the meeting was unsolved tasks in the field of therapy of the patients with radioactive iodine-refractory differentiated thyroid cancer. Nowadays, this group of patients still has a poor prognosis with respect to life expectancy. The experts are faced with some difficulties in choosing the treatment tactics in patients after radioiodine therapy have become ineffective and we observe disease progression. And still valid questions remain unsolved: when should doctors stop therapy using radioactive iodine? When should patient start therapy using targeted agents? What kind of targeted agent should specialist choose for treatment of this desiase? How should one manage the developing side effects against the backdrop of targeted therapy? These and some other problems have been discussed within the framework of this counsel.

About the authors

P O Rumyantsev

Endocrinology Research Center of the Ministry of Health of the Russian Federation

Email: pavelrum@gmail.com
д-р мед. наук, зам. дир. ФГБУ ЭНЦ по инновационному развитию, зав. отд. радионуклидной диагностики и терапии 117036, Russian Federation, Moscow, ul. Dmitria Ul'ianova, d. 11

V A Gorbunova

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., зав. отд. химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 2

S O Podvyaznikov

Russian Medical Academy of Postgraduate Education, of the Ministry of Health of the Russian Federation

д-р мед. наук, проф. каф. онкологии ФГБОУ ДПО РМАПО, гл. редактор научно-практического рецензируемого журнала «Опухоли головы и шеи», член редакционной коллегии по опухолям головы и шеи «Journal of Clinical Oncology» (русское издание), вице-президент Российского общества специалистов по опухолям головы и шеи 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1

N V Zhukov

Dmitriy Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology of the Ministry of Health of the Russian Federation

д-р мед. наук, зав. отд. оптимизации лечения онкологических заболеваний у подростков и взрослых, ФГБУ ФНКЦ ДГОИ им. Дмитрия Рогачева 117997, Russian Federation, Moscow, ul. Samory Mashela, d. 1

P A Isaev

A.F.Tsyba Medical Radiological Scientific Center, branch of National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation

д-р мед. наук, вед. науч. сотр., хирург-онколог, детский хирург отд-ния радиохирургического лечения закрытыми радионуклидами МРНЦ им. А.Ф.Цыба, филиала ФГБУ НМИРЦ 249036, Russian Federation, Obninsk, ul. Koroleva, d. 4

V V Krylov

A.F.Tsyba Medical Radiological Scientific Center, branch of National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation

д-р мед наук, зав. отд-нием радиохирургического лечения открытыми радионуклидами МРНЦ им. А.Ф.Цыба, филиал ФГБУ НМИРЦ 249036, Russian Federation, Obninsk, ul. Koroleva, d. 4

A M Mudunov

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., президент ООО «Российское общество специалистов по опухолям головы и шеи», рук. отд-ния опухолей головы и шеи ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 2

A A Rodichev

A.F.Tsyba Medical Radiological Scientific Center, branch of National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation

канд. мед. наук, врач отд-ния радиохирургического лечения открытыми радионуклидами МРНЦ им. А.Ф.Цыба, филиал ФГБУ НМИРЦ 249036, Russian Federation, Obninsk, ul. Koroleva, d. 4

E K Shavarova

People’s Friendship University; City Clinical Hospital №64

канд. мед. наук, доц. каф. пропедевтики внутренних болезней ФГАОУ ВО РУДН, ГБУЗ ГКБ №64 117198, Russian Federation, Moscow, ul. Miklukho-Maklaia, d. 6; 117292, Russian Federation, Moscow, ul. Vavilova, d. 61

References

  1. Durante C, Haddy N, Baudin E et al. Long - term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91 (8): 2892-9. doi: 10.1210/jc.2005-2838.
  2. Robbins R.J, Wan Q, Grewal R.K et al. Real - time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91 (2): 498-505. doi: 10.1210/jc.2005-1534.
  3. NCCN Clinical Practice Guidelines in Oncology. Thyroid Carcinoma Version 2.2015 http://www.nccn.org/professionals/physician_gls/ pdf/thyroid.pdf Последний доступ: 25.11.14.
  4. Pacini F, Castagna M.G, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow - up. ESMO Guidelines Working Group. Ann Oncol 2012; 23 (Suppl. 7): vii 110-9.
  5. Perros P et al. Guidelines for the management of thyroid cance. Clin Endocrinol 2014; 81 (S1): 1-22.
  6. Schlumberger M, Tahara M, Wirth L.J et al. Lenvatinib versus placebo in radioiodine - refractory thyroid cancer. N Engl J Med 2015; 372 (7): 621-30. doi: 10.1056/NEJMoa1406470.
  7. Milan A, Puglisi E, Ferrari L et al. Arerial hypertension and cancer. Int J Cancer 2014; 134: 2269-77.
  8. Mir O, Ropert S, Alexandre J et al. Hypertension as a surrogate marker for the activity of anti- VEGF agents. Ann Oncol 2009; 20 (5): 967-70.
  9. Maitland M.L, Bakris G.L, Black H.R et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596-604.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies